4th Quarter - Report
THE MCMANUS GROUP for GILEAD SCIENCES, INC.
Firm
Client
Income
$60,000
Expenses
—
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program. Issues related to federal funding for HIV prevention.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MCMANUS | — |
Medicare/Medicaid MMM
Support for EPIC Act - S. 832, and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Policies related to the Most Favored Nation Drug Pricing Model.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MCMANUS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.